Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Radiotherapy in Neoadjuvant ESCC
NCT06468670Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Cancer Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06468670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468670.